All in the Genes
By Marcy Darnovsky and Hank Greely,
Democracy
| 08. 31. 2008
Henry Greely inaccurately characterizes my organization, the Center for Genetics and Society, as "drawn to arguments against [inheritable human genetic enhancement] by the lure of naturalness" ["The Genetics of Fear," Issue #9].
I am not sure how Greely reached this conclusion. We explicitly ground our opposition in our commitments to social justice and equality. Procedures that produce (or claim to produce) genetically superior children for those with access to expensive technologies would all too likely exacerbate inequalities and lead to new forms of discrimination.
Greely seems enthusiastic about inheritable genetic modification, but he also recognizes that significant improvements are a long way off. He therefore dismisses proposals, such as the one offered by Jamie Metzl, for international agreements to prohibit socially undesirable human biotechnologies ["Brave New World War," Issue #8]. He disparages efforts at international regulation as "neither progressive nor wise," without mentioning that similar regulations are already in effect, and working well, in over four dozen countries. The United States should join this growing international consensus.
Greely warns ominously that regulating biotechnology "would almost certainly...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...